Clinical Trial Update: the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient [Phase 3]

View source ↗

Summary

This clinical trial update describes a Phase 3 study comparing an idarubicin-strengthened pretreatment regimen with a conventional busulfan/cyclophosphamide pre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• BUSULFAN (Busulfan)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Idarubicin (idarubicin)

Snippet

Sponsor: Guangxi Medical University | Conditions: Acute Myeloid Leukemia | Phase 3 | Status: UNKNOWN